H.C. Wainwright lowered the firm’s price target on Mirum Pharmaceuticals to $60 from $63 and keeps a Buy rating on the shares post the Q3 report. The analyst continues to see significant upside for the shares given the anticipated growth of the Livmarli franchise, along with potential expansions into multiple liver diseases on the horizon.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MIRM:
- Mirum Pharmaceuticals reports Q3 EPS (57c), consensus (65c)
- Cantor Fitzgerald biotech analyst holds an analyst/industry conference call
- Cantor starts Mirum at Overweight on inhibitor portfolio expansion
- Mirum Pharmaceuticals initiated with an Overweight at Cantor Fitzgerald
- Mirum says FDA extends review of sNDA for LIVMARLI
Questions or Comments about the article? Write to editor@tipranks.com